- 2024 - 2029 RNA 動的解析による固形腫瘍を破壊可能なGAIA-102の分化誘導機構の解明
- 2024 - 2028 Elucidation of inflammation regulatory mechanisms in central nervous system autoimmune diseases
- 2023 - 2026 ヘミチャネル阻害薬を用いたαシヌクレイン伝播阻止による多系統萎縮症の治療法開発
- 2023 - 2026 免疫学的視点からみた中枢性神経障害性疼痛の病態解明ならびに新規治療法開発
- 2024 - 2025 精神神経疾患におけるミクログリア活性化とは何か?ヒト細胞を用いた疾患横断的研究
- 2022 - 2025 単一細胞RNA解析による多系統萎縮症増悪性ミクログリア亜群の同定と同細胞標的療法
- 2022 - 2025 Detection of ALS origin with reference to calcium-binding proteins, those generate glial inflammation
- 2022 - 2025 What is microglial activation in neuropsychiatric disorders? A cross-disease study using human cells.
- 2021 - 2024 グリアコネキシン低分子量イソフォーム発現エキソソームによる脱髄炎の悪化と治療開発
- 2020 - 2023 A novel model of multiple sclerosis and multiple system atrophy that are differentially manifested by the time of abnormal protein expression
- 2020 - 2023 活性化グリア細胞制御による進行性多発性硬化症および多系統萎縮症の画期的治療法開発
- 2019 - 2022 Significance of and treatment against galectin-3 and p22 accompanied with glial inflamation in ALS spinal cord
- 2019 - 2022 Development of treatment for multiple sclerosis based on rice consumption, a newly identified environmental risk factor
- 2019 - 2022 Establishment of primary-progressive multiple sclerosis (PPMS)/multiple system atrophy (MSA) mice model
- 2019 - 2022 Misfold protein removal therapy with CCR2-positive cells from peripheral nerves in motor neuron disease
- 2019 - 2022 Elucidation of autoimmune mechanisms and developement of novel therapy for demyelinating diseases based on genetic and envrionmental risk factors and disease-specific anti-neural antibodies
- 2018 - 2021 A novel mice model of MSA by overexpression of mutant alpha-synuclein in oligodendroglia in a temporarily restrictive manner using Tet-off system
- 2017 - 2020 Development of new MR neurography with simultaneous T2 mapping
- 2017 - 2020 Elucidation of the role of glial cell in tau transmission and axonal degeneration in Alzheimer's disease and targeted therapy with glial cell
- 2017 - 2019 Establishment of world-premier pachymeningitis animal model and development of new therapeutic option targeting TGF-beta.
- 2016 - 2019 The origin of retrograde motor neuron degeneration elicited by activated microglia in pre- or early-symptomatic spinal cord tissues from human patients with amyotrophic lateral sclerosis
- 2016 - 2019 Development of new therapeutic options for multiple sclerosis by suppression of CNS immune system augmentation due to the malfunction of astroglia connexin
- 2016 - 2019 Elucidation of mechanisms for destruction and fixation of glia-syncytium in demyelinating diseases by whole-genome sequencing and immunohistochemical analysis.
- 2015 - 2018 Retro-element insertion polymorphism in pathogenic Th17 cells specific for multiple sclerosis and its action
- 2015 - 2018 Elucidation of pathomecanisms via CCR2 positive monocyte-dependent neuroprotection in the amyotrophic lateral sclerosis model mice.
- 2015 - 2018 Therapy for multiple sclerosis targeting gamma-delta T cells and innate immunity based on genome-wide association studies in Japanese population
- 2013 - 2018 Elucidasion of functional contribution of glial dysturbances in pathomechanisms of demyelinating diseases and schizophrenia and development of new therapeutic options
- 2014 - 2017 Extensive disruption of energy transports via glial syncytium in demyelinating diseases
- 2014 - 2017 Development of apomorphine therapy targeting insulin resistance in Alzheimer's disease
- 2013 - 2016 Complete remission induction therapy development of multiple sclerosis by selective - timed activation of the protective microglia
- 2013 - 2016 connexin cytopathy in the pathogenesis of demyelinating disorders
- 2009 - 2011 ALSに対するG-CSFの運動ニューロン保護作用の解明と髄腔内持続投与療法の開発
Show all